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Background. The efficacy of umbilical cord blood
transplantation (UCBT) as treatment for acute
myeloid leukaemia (AML) relies on immune-
mediated graft-versus-leukaemia effects. Previous
studies have suggested a strong association
between graft-versus-host disease (GVHD) occur-
rence and graft-versus-leukaemia effects after allo-
geneic hematopoietic cell transplantation.
Methods. Here, we evaluated the kinetics of relapse
rate in correlation with GVHD occurrence after
UCBT. The kinetics of relapse rate over time in
correlation to GVHD occurrence were assessed by
calculating the relapse rate per patient-year within
sequential 90-day intervals. The impact of GVHD
on relapse and mortality was further studied in
multivariate Cox models handling GVHD as a time-
dependent covariate.
Results. The study included data from 1068
patients given single (n = 567) or double
(n = 501) UCBT. The proportion of patients with
grade II, III and IV acute GVHD was 20%, 7%
and 4%, respectively. At 2 years, the cumulative
incidence of chronic GVHD was 42%, the cumu-
lative incidence of relapse was 32%, and overall
survival was 32% as well. Relapse rates declined
gradually over time during the first 30 months
after transplantation. There was a possible sug-
gestion that grade II–IV acute (HR = 0.8, P = 0.1)
and chronic (HR = 0.65, P = 0.1) GVHD
decreased relapse risk. However, grade II–IV
acute GVHD significantly increased early (the
first 18 months after UCBT) mortality (HR = 1.3,
P = 0.02), whilst chronic GVHD increased each
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early (HR = 2.7, P < 0.001) and late (HR = 4.9,
P < 0.001) mortality after UCBT.
Conclusions. The occurrence of grade II–IV acute or
chronic GVHD each increases overall mortality
after UCBT for AML mitigating the possible graft-
versus-leukemia effect of GVHD.
Keywords: acute myeloid leukaemia, graft-versus-
host disease, graft-versus-leukaemia effects,
umbilical cord blood transplantation.
Background
Allogeneic umbilical cord blood transplantation
(UCBT) is a treatment option for many patients with
acute myeloid leukaemia (AML) who lack an HLA-
matched donor [1–4]. Its efficacy relies on immune-
mediated graft-versus-leukaemia (GVL) effects [5–
10]. Following allogeneic bone marrow (BM) or
peripheral blood stem cell (PBSC) transplantation,
there is a strong association between occurrence of
graft-versus-host disease (GVHD) anda lower risk of
AML relapse [11–16]. However, occurrence of GVHD
has also been associated with higher risk of nonre-
lapsemortality, and thusonlymilder formsofGVHD
(grade 1 acute and limited chronic) have been
associated with improved overall survival [13].
Umbilical cord blood transplantation has been
associated with a lower incidence of severe acute
and/or chronic GVHD that would be expected
based on the degree of donor-recipient human
leukocyte antigen (HLA) mismatch [17]. Further, it
has been suggested that acute GVHD following
UCBT responds better to corticosteroids than acute
GVHD following BM or PBSC transplantation [18,
19]. Three recent large studies assessed the impact
of GVHD on outcomes after UCBT and yielded
conflicting results [20–22]. Lazaryan et al. observed
no association between acute (either grade II–IV or
grade III–IV) or chronic (limited or extensive) GVHD
and nonrelapse mortality after UCBT (n = 711) [20].
Acute GVHD did not impact the relapse incidence.
In contrast, chronic GVHD was associated with a
lower risk of relapse, but only in the subgroup of
patients receiving double UCBT. More recently,
Kanda et al. observed that acute and chronic GVHD
each decreased the risk of relapse in a large cohort
of UCBT recipients (n = 2558) [21]. However, only
milder forms of GVHD (grade 1–2 acute and limited
chronic GVHD) were associated with better survival
due to a strong association between severe forms of
GVHD and nonrelapse mortality. Finally, in the
study by Chen et al., grade III–IV acute GVHD was
associated with worse survival, whilst occurrence of
chronic GVHD did not have a significant impact on
overall survival [22].
Previous studies might have overestimated the
beneficial impact of GVHD on relapse incidence
given the tight association between GVHD and
nonrelapse mortality (since relapse and nonre-
lapse mortality are competing events). In order to
circumvent this potential limitation, Inamoto
et al. proposed a new way of assessing the impact
of covariate (including time-dependent covariate)
on relapse incidence that is not affected by
competing risk [23]. This method is based on
the calculation of the rate of relapse per patient-
year for each condition within sequential 90-day
intervals after transplantation, and smoothed
estimates of the event rates obtained by fitting a
Poisson regression model to the observed
numbers of events, using cubic spline terms for
time. This method allows assessing the evolution
of the hazard ratio for the risk of relapse over
time and is not affected by competing risks. Here,
we used this statistical approach to revisit the
graft-versus-leukaemia effects after UCBT. Main
observations were that although there was per-
haps a suggestion (nonstatistically significant) for
a lower incidence of relapse with the development
of grade II–IV acute or chronic GVHD, grade II–IV
acute GVHD increased the risk mortality the first
18 months after transplantation, whilst chronic
GVHD increased the risk of mortality both
before and particularly after 18 months following
UCBT.
Methods
Data collection and definitions
This survey is a retrospective study performed by
the Acute Leukemia Working Party (ALWP) of the
European society for Blood and Marrow Trans-
plantation (EBMT) and by Eurocord. EBMT registry
is a voluntary working group of more than 500
transplant centres, participants of which are
required once a year to report all consecutive stem
cell transplantations and follow-up. Audits are
routinely performed to determine the accuracy of
the data. Eurocord collects data on UCBT per-
formed in >50 countries worldwide and >500
transplant centres, mainly EBMT centres.
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Inclusion criteria were adult (>18 years) patients,
primary or secondary AML, and first single or
double UCBT between 2004 and 2014.
RIC was defined as use of fludarabine (Flu) asso-
ciated with <6 Gy TBI, or busulfan ≤8 mg kg1,
melphalan ≤140 mg m2 or other nonmyeloabla-
tive drugs, as previously reported [13, 24, 25].
Human leukocyte antigen (HLA) compatibility
requirements followed the current practice of anti-
gen level typing for HLA-A and HLA-B and allele
level typing of HLA-DRB1. CB units were 4–6/6
HLA-A, HLA-B and HLA-DRB1 matched to the
recipient and to the other unit in case of double
UCBT in most patients. However, more recently,
some centres are no longer matching the CB units
between them with regard to HLA based on the
study by Avery et al. [26]. HLA disparities between
each unit and the recipient and between the two
units were not necessarily at the same loci. Grad-
ing of acute and chronic GVHD was performed
using established criteria [27].
For the purpose of this study, all necessary data
were collected according to EBMT and Eurocord
guidelines.
Ethics
The scientific boards of the ALWP of EBMT and of
Eurocord approved this study.
Statistical analyses
Data from all patients meeting the inclusion/
exclusion criteria were included in the analyses.
Start time was date of transplant for all end-points.
Neutrophil engraftment was defined as first of
three consecutive days with a neutrophil count of
at least 0.5 9 109 per L.
To evaluate the relapse incidence, patients dying
either from direct toxicity of the procedure or from
any other cause not related to leukaemia were
censored. Nonrelapse mortality was defined as
death without experiencing disease recurrence.
Patients were censored at the time of relapse or of
the last follow-up. Cumulative incidence functions
were used for relapse incidence and nonrelapse
mortality in a competing risk setting, since death
and relapse were competing together.
For estimating the cumulative incidence of chronic
GVHD, death was considered as a competing event.
Overall (OS) and leukaemia-free (LFS) survivals
were estimated using the Kaplan–Meier estimates.
Univariate analyses were done using Gray’s test for
cumulative incidence functions and log-rank test
for OS and LFS.
Acute and chronic GVHD were assessed as time-
dependent covariates. Patients at risk of relapse or
mortality were classified in three mutually exclu-
sive conditions based on their histories of acute
GVHD or chronic GVHD as previously reported by
Inamoto et al. [23]: grades 0–I acute GVHD with-
out chronic GVHD (hereafter designated ‘no
GVHD’), grades II–IV acute GVHD without chronic
GVHD (hereafter designated ‘acute GVHD’) or
chronic GVHD with or without grade II–IV acute
GVHD (hereafter designated ‘chronic GVHD’). All
patients were first classified in the ‘no GVHD’
group until the onset of acute GVHD or chronic
GVHD. Patients with ‘acute GVHD’ were classified
in that condition, regardless of whether acute
GVHD had resolved, until the onset of chronic
GVHD if it occurred. Patients with ‘chronic GVHD’
were classified in that condition thereafter. The
impact of GVHD on relapse and mortality was
illustrated by calculating the rate of relapse per
patient-year for each condition within sequential
90-day intervals after transplantation, and
smoothed estimates of the event rates obtained
by fitting a Poisson regression model to the
observed numbers of events, using cubic spline
terms for time. In a second set of analyses, only
patients who achieved stable engraftment were
included in the analyses.
In addition to the analyses defined above, we also
used time-dependent Cox models to assess the
association between GVHD and risks of relapse,
nonrelapse mortality and overall mortality.
All tests were two sided. The type I error rate was
fixed at 0.05 for determination of factors associated
with time to event outcomes. Statistical analyses
were performed with SPSS 19 (SPSS Inc, Chicago,
IL) and R 2.13.2 (R Development Core Team,
Vienna, Austria) software packages.
Results
Outcomes after UCBT
The study included data from 1068 patients given
single (n = 567) or double (n = 501) UCBT. Median
patient age at transplantation was 45.5 (range, 18–
73) years (Table 1).
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Overall, grades II, III and IV acute GVHD were
observed in 203 (20%), 77 (7%) and 42 (4%)
patients, respectively. The 100-day cumulative
incidence of grade II–IV acute GVHD was 31%
(95% CI, 28–34%). Median time from transplanta-
tion to onset of grade II–IV acute GVHD was 29
(range, 4–229) days. In multivariate analyses,
double UCBT was associated with a higher inci-
dence of grade II–IV acute GVHD (HR = 1.5, 95%
CI: 1.1–2.0, P = 0.009).
The 2-year cumulative incidence of chronic GVHD
was 42% (95% CI, 37–46%) with 50% limited and
50% extensive chronic GVHD. Median time from
transplantation to onset of chronic GVHD was 147
(range, 61–1230) days. Amongst chronic GVHD
patients, 101 (44%) had a prior history of grade II–
IV acute GVHD. In multivariate analyses, patients
with advanced disease had a lower incidence of
chronic GVHD (HR = 0.5, 95% CI: 0.3–0.7,
P < 0.001).
With a median follow-up of 35 months, 2-year
incidences of relapse and nonrelapse mortality
were 32% (95% CI, 29–35%) and 38% (95% CI,
35–41%), respectively. Two-year OS and LFS were
32% (95% CI, 30–36%) and 30% (95% CI, 27–33%),
respectively.
Eight hundred and twenty-six patients (77%)
achieved neutrophil engraftment. Restricting the
analyses to the 826 patients with neutrophil
engraftment, grades II, III and IV acute GVHD were
observed in 176 (22%), 71 (9%) and 34 (4%)
patients, respectively. The 100-day cumulative
incidence of grade II–IV acute GVHD was 34%
(95% CI, 31–38%). The 2-year cumulative inci-
dence of chronic GVHD was 44% (95% CI, 39–49%)
with 52% limited and 48% extensive chronic
GVHD. Two-year incidences of relapse and nonre-
lapse mortality were 33% (95% CI, 30–36%) and
33% (95% CI, 29–36%), respectively. Two-year OS
and LFS were 37% (95% CI, 34–41%) and 34%
(95% CI, 31–38%), respectively.
Evolution of relapse rates after UCBT and impact of GVHD
As shown in Fig. 1, relapse rates per patient/year
declined gradually over time during the first
30 months after transplantation; this was also
the case when analyses were restricted to patients
with neutrophil engraftment (Figure S1). In multi-
variate analyses, factors associated with higher
relapse incidences included being transplanted in
CR3+ (HR = 2.2, 95% CI: 1.3–3.7, P = 0.003) or in
advanced disease (HR = 3.2, 95% CI: 2.4–4.3,
P < 0.001) and poor risk cytogenetics (HR = 2.6,
95% CI: 1.3–5.5, P = 0.01), whilst there was a
suggestion for a higher incidence of relapse in
patients given grafts after RIC conditioning
(HR = 1.3, 95% CI: 1.0–1.7, P = 0.08). Interest-
ingly, the use of RIC conditioning was associated
with a higher incidence of relapse the first
18 months after transplantation (HR = 1.4, 95%
CI: 1.1–1.9, P = 0.02) but not thereafter (HR = 0.6,
95% CI: 0.3–1.3, P = 0.2).
Looking at the impact of GVHD on relapse, the
relapse rate per patient/year from 3 to 6 months
was lower in patients with acute GVHD than in
patients without GVHD (Fig. 1). Thereafter, the
relapse/rate per patient-year was comparable in
acute GVHD and no GVHD patients. Regarding
chronic GVHD, the relapse rate per patient/year
tended tobe lower than in thenoGVHDand theacute
GVHD group from 9 to 30 months after transplanta-
tion. In multivariate time-dependent Cox models,
therewasasuggestion fora lower incidenceof relapse
in patients with grade II–IV acute GVHD (HR = 0.78;
95% CI: 0.60–1.1, P = 0.1) and those with chronic
GVHD (HR = 0.65; 95% CI: 0.37–1.12, P = 0.1).
However, these associations did not reach statistical
significance (Table 2) .
Separating grade II and grade III–IV acute as well as
limited and extensive chronic GVHD, there was no
statistically significant association between occur-
rence of GVHD (of any grade) and relapse risk
(Table 3). Similar results were observed when the
analyses were restricted to patients who achieved
neutrophil engraftment (Table S1). However, there
was a suggestion of an interaction between single or
double UCBT and the impact of grade III–IV acute
GVHD on the risk of relapse (P = 0.07), whilst no
interactions were observed for grade II acute or
chronic GVHD. Finally, the risk of relapse was
similar in patients given 3/6 or 4/6 HLA-matched
UCB versus those given 5/6 or 6/6 HLA-matched
UCBT (HR = 1.2; 95% CI: 0.9–1.6, P = 0.3).
Evolution of nonrelapse mortality rates after UCBT and impact of
GVHD
As shown in Fig. 2, nonrelapse mortality rates per
patient/year declined gradually over time during
the first 30 months after transplantation; this was
also the case when analyses were restricted to
patients with neutrophil engraftment (Figure S2).
GvL after UCBT for AML / F. Baron et al.
4 ª 2017 The Association for the Publication of the Journal of Internal Medicine
Journal of Internal Medicine
In multivariate analyses, factors associated with a
higher incidence of nonrelapse mortality included
higher patient age (HR = 1.02; 95% CI: 1.01–1.03,
P = 0.002) and advanced disease (HR = 1.6; 95%
CI: 1.2–2.2, P < 0.001), whilst the use of a RIC
regimen was associated with a lower incidence of
nonrelapse mortality (HR = 0.6, 95% CI: 0.4–0.7,
P < 0.001). Each of these factors was significantly
associated with early (≤18 months after UCBT)
nonrelapse mortality, whilst none of them
impacted late (>18 months after UCBT) nonrelapse
mortality.
Looking at the impact of GVHD on nonrelapse
mortality, occurrence of grade II–IV acute GVHD
increased global (HR = 1.8, 95% CI: 1.4–2.3,
P < 0.001) and early (HR = 1.8, 95% CI: 1.4–2.4,
P < 0.001) nonrelapse mortality, whilst chronic
GVHD was associated with higher global (HR =
2.7, 95% CI: 1.6–4.4, P < 0.001), early (HR = 2.3,
95% CI: 1.3–4.1, P = 0.005) and late (HR = 3.8,
95% CI: 1.2–11.4, P = 0.02) nonrelapse mortality.
Separating grade II and grade III–IV acute as well
as limited and extensive chronic GVHD, there was
a statistically significant association between
occurrence of GVHD grade III–IV acute (HR = 4.1,
95% CI: 2.8–6.0, P < 0.001) and of extensive
chronic (HR = 5.3, 95% CI: 3.6–7.9, P < 0.001)
GVHD and the risk of nonrelapse mortality
(Table 3). In contrast, grade II acute GVHD
(HR = 0.8, 95% CI: 0.5–1.2, P = 0.3) as well as
limited chronic (HR = 1.1, 95% CI: 0.6–2.1,
P = 0.7) GVHD was not associated with nonrelapse
mortality. Comparable results were observed when
the analyses were restricted to patients who
achieved neutrophil engraftment (Table S1).
Finally, there was no interaction between single
or double UCBT and the impact of GVHD on the
risk of nonrelapse mortality.
Evolution of mortality after UCBT and impact of GVHD
As shown in Fig. 3, mortality rates per patient/year
declined gradually over time during the first
30 months after transplantation; this was also
the case when analyses were restricted to patients
with neutrophil engraftment (Figure S3). In multi-
variate Cox analyses, higher patient age
(HR = 1.01; 95% CI: 1.00–1.02, P = 0.001) and
advanced disease (HR = 2.3; 95% CI: 1.8–2.8,
P < 0.001) increased global (and early) mortality,
whilst RIC regimen was associated with a lower
risk of global (as well as early and late) mortality
(HR = 0.8, 95% CI: 0.6–0.9, P = 0.006).
Looking at the impact of GVHD on mortality, grade
II–IV acute GVHD increased the mortality rate per
patient/year from 1 year to 21 months after trans-
plantation, whilst chronic GVHD increased mor-
tality throughout the study period. In multivariate
time-dependent Cox models, grade II–IV acute
GVHD significantly increased mortality (HR =
1.29; 95% CI: 1.05–1.57, P = 0.01). Separating
early and late mortality, acute GVHD increased
early but not late mortality. In contrast, chronic
GVHD increased not only global (HR = 2.84; 95%
CI: 2.2–3.7, P < 0.001) mortality but also early and
Fig. 1 Evolution of relapse
rates according to GVHD
status. Rates were calculated
within sequential 90-day
intervals for patients without
GVHD (shown in blue), for
patients with grades II–IV acute
GVHD (shown in green) or for
patients with chronic GVHD
(shown in red). Small symbols
represent the actual relapse
rates for each 90-day interval.
The smoothed rates were
plotted as curves for each
condition.
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late mortality. Separating grade II and grade III–IV
acute as well as limited and extensive chronic
GVHD, there was a statistically significant associ-
ation between occurrence of grade III–IV acute
(HR = 2.8, 95% CI: 2.0–3.9, P < 0.001) and of
extensive chronic (HR = 2.3, 95% CI: 1.7–3.0,
P < 0.001) GVHD and the risk of mortality
(Table 3). In contrast, grade II acute (HR = 0.8,
95% CI: 0.6–1.1, P = 0.2) as well as limited chronic
(HR = 0.9, 95% CI: 0.7–1.3, P = 0.6) GVHD was not
associated with overall mortality. Comparable find-
ings were observed when the analyses were
restricted to patients who achieved neutrophil
engraftment (Table S1).
Impact of ATG
We restricted the analyses assessing the impact of
ATG on UCBT outcomes in the subgroup of
patients with sustained engraftment in order to
avoid the possible confounding impact of ATG on
neutrophil engraftment. In multivariate analyses,
the use of ATG was associated with a lower
incidence of grade II (HR = 0.4, 95% CI: 0.3–0.6,
Table 1 Patient and transplant characteristics
UCBT (n = 1068)
Median patient age, y (range) 45.5 (18–73)
Median follow-up,
months (range)
35 (0–118)
Year of transplantation,
median (range)
2011 (2004–2014)
Recipient gender M, # (%) 525 (49)
Karnofsky score, # (%)
>80 572 (54)
≤80 301 (28)
Missing 195 (18)
Disease status, # (%)
CR1 458 (43)
CR2 291 (27)
CR3+ 42 (4)
>CR 209 (20)
Ukn 68 (6)
Cytogenetics, # (%)
Good riska 64 (6)
Intermediate riskb 527 (49)
High riskc 117 (11)
Not reported/failed 360 (34)
Graft type
Single UCBT 567 (53)
Double UCBT 501 (47)
TNC, median (range) 4.2 (0.4–13.7)
Number of HLA disparities, # (%)
0–1 mismatch 256 (24)
2–4 mismatches 594 (56)
Missing 218 (20)
Conditioning regimen, # (%)
MAC 505 (47)
TCF 57 (5)
TBF 208 (19)
Other TBI-based 83 (8)
Other 157 (15)
RIC 546 (51)
TCF 319 (30)
TBF 38 (4)
Other TBI-based 55 (5)
Other 134 (12)
Missing 17 (1)
Recipient CMV seronegative, # (%) 267 (31.9)
Table 1 (Continued )
UCBT (n = 1068)
ATG, # (%)
Yes 476 (45)
No 394 (37)
Missing 198 (18)
Postgrafting immunosuppression, # (%)
CSP alone 70 (7)
CSP + MMF 651 (61)
CSP + Predisolone 171 (16.0)
CSP + MTX 38 (4)
Other 138 (13)
MAC, myeloablative conditioning; RIC, reduced-intensity
conditioning (as defined previously[25]); Y, year; M, male;
CR, complete remission; #, number of patients; TCF, total
body irradiation (TBI), cyclophosphamide and fludara-
bine; TBF, thiotepa, busulfan and fludarabine; ATG, anti-
thymocyte globulins; TNC, total nucleated cells; CSP,
cyclosporine A; MMF, mycophenolate mofetil.
adefined as t(8;21), t(15;17), inv or del (16), or acute
promyelocytic leukaemia, these abnormalities only or
combined with others; bdefined as all cytogenetics not
belonging to the good or high risk (including trisomias);
cdefined as 11q23 abnormalities, complex karyotype,
abnormalities of chromosomes 5 and 7.
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Table 2 Multivariate Cox models I (3 groups of GVHD)
Variable
Relapse Nonrelapse mortality Mortality
HR
95% CI for
HR P HR
95% CI for
HR P HR
95% CI for
HR P
Overall
GVHD
aGVHD only grade 0–I (ref) – – – – – – – – –
aGVHD only grade II-IV 0.78 0.58, 1.06 0.11 1.8 1.40, 2.31 <0.001 1.29 1.05, 1.57 0.01
cGVHD with or without aGVHD 0.65 0.37, 1.12 0.12 2.69 1.61, 4.48 <0.001 2.84 2.19, 3.67 <0.001
Patient age at transplant 1 1.00, 1.01 0.34 1.02 1.01, 1.03 0.002 1.01 1.00, 1.02 0.001
Disease status at transplant
CR1 (ref) – – – – – – – – –
CR2 1.1 0.81, 1.51 0.53 1.03 0.78, 1.36 0.85 1.09 0.88, 1.35 0.41
CR3+ 2.17 1.29, 3.65 0.003 0.83 0.43, 1.58 0.57 1.27 0.85, 1.90 0.25
Advanced disease 3.21 2.40, 4.28 <0.001 1.64 1.22, 2.20 <0.001 2.25 1.83, 2.77 <0.001
Cytogenetic
Good (ref) – – – – – – – – –
Interm 1.92 0.97, 3.80 0.06 0.58 0.38, 0.89 0.01 1 0.69, 1.45 0.99
Poor 2.64 1.26, 5.53 0.01 0.59 0.34, 1.03 0.06 1.05 0.68, 1.63 0.82
NA/failed 1.48 0.71, 3.06 0.29 0.88 0.55, 1.38 0.57 1.15 0.77, 1.71 0.49
Graft typeDCBT versus SCBT 1 0.78, 1.28 0.98 0.8 0.63, 1.01 0.07 0.85 0.72, 1.02 0.07
Conditioning typeRIC versus MAC 1.28 0.97, 1.68 0.08 0.57 0.43, 0.74 <0.001 0.77 0.63, 0.93 0.006
Before 18 months
GVHD
aGVHD only grade 0–I (ref) – – – – – – – – –
aGVHD only grade II-IV 0.81 0.59, 1.11 0.2 1.83 1.41, 2.38 <0.001 1.29 1.05, 1.59 0.02
cGVHD with or without aGVHD 0.63 0.34, 1.17 0.14 2.32 1.28, 4.20 0.005 2.69 2.03, 3.57 <0.001
Patient age at transplant 1 0.99, 1.01 0.63 1.02 1.00, 1.03 0.004 1.01 1.00, 1.02 0.009
Disease status at transplant
CR1 (ref) – – – – – – – – –
CR2 1.01 0.72, 1.42 0.96 0.99 0.73, 1.32 0.92 1.03 0.82, 1.29 0.8
CR3+ 1.76 0.96, 3.23 0.07 0.92 0.48, 1.76 0.79 1.21 0.78, 1.88 0.4
Advanced disease 3.19 2.36, 4.30 <0.001 1.64 1.21, 2.22 0.001 2.26 1.83, 2.79 <0.001
Cytogenetic
Good (ref) – – – – – – – – –
Interm 1.72 0.83, 3.57 0.15 0.55 0.35, 0.86 0.008 0.94 0.64, 1.38 0.74
Poor 2.43 1.11, 5.31 0.03 0.52 0.29, 0.94 0.03 0.97 0.61, 1.53 0.89
NA/failed 1.26 0.58, 2.74 0.56 0.78 0.49, 1.25 0.3 1.03 0.68, 1.55 0.89
G raft typeDCBT versus SCBT 1.03 0.79, 1.33 0.85 0.79 0.62, 1.01 0.06 0.85 0.71, 1.02 0.08
Conditioning typeRIC versus MAC 1.41 1.05, 1.88 0.02 0.55 0.42, 0.73 <0.001 0.8 0.65, 0.97 0.03
After 18 months
GVHD
aGVHD only grade 0–I (ref) – – – – – – – – –
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P < 0.001) and grade III–IV (HR = 0.5, 95% CI:
0.3–0.8, P = 0.01) acute GVHD. In contrast, there
was no impact of ATG on chronic GVHD
(HR = 1.5, 95% CI: 0.9–2.4, P = 0.1). Importantly,
there was no association between ATG and the
risk of relapse (HR = 0.9, 95% CI: 0.6–1.3,
P = 0.5) (Table S1). However, ATG was associated
with a significantly higher incidence of nonre-
lapse mortality (HR = 2.2, 95% CI: 1.5–3.4,
P < 0.001) translating to worse OS (HR = 1.4,
95% CI: 1.1–1.9, P = 0.02). Specifically, 49 out
of 315 patients (16%) not given ATG died within
the first 100 days after transplantation because
of GVHD [n = 15 (5%)], AML [n = 13 (4%)], infec-
tion [n = 11 (3%)], second malignancy [n = 1
(0.5%)] or other [n = 9 (3%)]. During the same
time period, 74 out of 379 ATG patients (20%)
died because of GVHD [n = 12 (3%)], AML [n = 22
(6%)], infection [n = 20 (5%)], second malignancy
[n = 3 (1%)], haemorrhage [n = 3 (1%)] or other
[n = 14 (4%)].
Discussion
A few recent studies have assessed the impact of
GVHD on outcomes after UCBT. These studies
assessed the impact of GVHD on transplantation
outcomes throughout the study period and reported
conflicting results [20–22]. Here we assessed the
impact of GVHD on early (the first 18 months after
transplantation) and late (thereafter) transplanta-
tion outcomes in a large cohort of AML patients
given single or double UCBT by calculating the rate
of relapse per patient-year for each condition within
sequential 90-day intervals after allo-SCT (this
method allows assessment of the evolution of the
HR for the risk of relapse over time and is not
affected by competing risks [23]) and by performing
conventional Cox models where acute and chronic
GVHD were handled as time-dependent covariates.
Several observations were made.
First, there was a suggestion that both grade II–IV
acute and chronic GVHD perhaps slightly
decreased the incidence of relapse although it did
not reach statistical significance (perhaps due to
the relatively low number of patients in the two
GVHD groups). Interestingly, our data suggest that
the protective effects of acute and chronic GVHD
on the risk of relapse do not occur at the same
timing. Specifically, acute GVHD seemed to protect
against GVHD only the first 6 months after
Table 2 (Continued )
Variable
Relapse Nonrelapse mortality Mortality
HR
95% CI for
HR P HR
95% CI for
HR P HR
95% CI for
HR P
aGVHD only grade II-IV 0.58 0.22, 1.55 0.28 1.58 0.62, 4.02 0.33 1.26 0.62, 2.56 0.53
cGVHD with or without aGVHD 0.84 0.22, 3.13 0.79 3.76 1.24, 11.44 0.02 4.87 2.41, 9.85 <0.001
Patient age at transplant 1.02 0.99, 1.05 0.21 1.02 0.99, 1.05 0.24 1.03 1.00, 1.05 0.04
Disease status at transplant
CR1 (ref) – – – – – – – – –
CR2 1.94 0.81, 4.62 0.14 1.63 0.67, 3.97 0.28 1.92 0.99, 3.72 0.05
CR3+ 4.32 1.41, 13.21 0.01 0 0.00, Inf 1 1.24 0.45, 3.44 0.68
Advanced disease 2.52 0.79, 8.04 0.12 1.68 0.47, 6.02 0.42 2.33 0.97, 5.56 0.06
Cytogenetic
Good (ref) – – – – – – – – –
Interm 3.06 0.40, 23.21 0.28 1.42 0.18, 11.46 0.74 1.57 0.36, 6.81 0.55
Poor 2.93 0.28, 30.67 0.37 2.9 0.29, 28.98 0.37 1.94 0.37, 10.25 0.43
NA/failed 3.83 0.45, 32.41 0.22 4.83 0.55, 42.11 0.15 3.55 0.76, 16.51 0.11
Graft typeDCBT versus SCBT 0.83 0.40, 1.72 0.62 1.01 0.43, 2.37 0.99 0.9 0.50, 1.61 0.72
Conditioning typeRIC versus MAC 0.59 0.26, 1.34 0.2 0.63 0.23, 1.73 0.37 0.5 0.26, 0.97 0.04
GVHD, graft-versus-host disease; aGVHD, acute GVHD; cGVHD, chronic GVHD; CR, complete remission; DCBT, double
umbilical cord blood transplantation; SCBT single umbilical cord blood transplantation; RIC, reduced-intensity
conditioning; MAC, myeloablative conditioning.
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transplantation, whilst perhaps a more durable
protection occurred with chronic GVHD.
Secondly and more importantly, occurrence of
both acute and chronic GVHD increased overall
mortality. Interestingly, separating early
(≤18 months after UCBT) and late mortality, acute
GVHD increased early but not late mortality, whilst
chronic GVHD increased both. Interestingly, the
negative impact of acute GVHD was restricted to
grade III–IV acute GVHD (there was no impact of
grade II acute GVHD), whilst the negative impact of
chronic GVHD was limited to extensive chronic
GVHD. These results differ from those recently
reported by Kanda et al. who observed better
overall survival associated with the development
of grade I–II acute GVHD and/or limited chronic
GVHD [21] and those reported by Chen et al. who
observed no impact of chronic GVHD on overall
survival [22]. These differences could by partly due
to the fact that both adults and children were
included in the study by Chen et al. and that the
analysis of the impact of chronic GVHD on survival
in the Kanda et al. study was stratified for prior
history of acute GVHD. Importantly, our observa-
tions suggest that strategies aimed at better pre-
venting GVHD are also requested in the UCBT
setting. In our study, the use of ATG was associ-
ated with a lower incidence of grade II–IV and
grade III–IV acute GVHD but not with chronic
GVHD (in contrast to what has been observed
when peripheral blood stem cells are used as stem
Table 3 Multivariate Cox models II (five groups of GVHD)
Variable
Relapse Nonrelapse Mortality Mortality
HR
95% CI
for HR P HR
95% CI
for HR P HR
95% CI
for HR P
GVHD
aGVHD only grade 0–I (ref) – – – – – – – – –
aGVHD only grade II 0.85 0.58, 1.23 0.39 0.77 0.47, 1.23 0.27 0.81 0.60, 1.10 0.19
aGVHD only grade III-IV 0.71 0.34, 1.45 0.34 4.06 2.75, 6.00 <0.001 2.80 2.02, 3.87 <0.001
cGVHD limited with or
without aGVHD
0.97 0.64, 1.48 0.89 1.12 0.62, 2.05 0.70 0.91 0.65, 1.27 0.58
cGVHD extensive with or
without aGVHD
0.70 0.40, 1.21 0.21 5.30 3.55, 7.91 <0.001 2.25 1.69, 3.00 <0.001
Patient age at transplant 1.00 0.99, 1.01 0.71 1.02 1.01, 1.03 0.002 1.01 1.01, 1.02 <0.001
Disease status at transplant
CR1 (ref) – – – – – – – – –
CR2 1.10 0.79, 1.53 0.56 1.03 0.75, 1.40 0.87 1.07 0.85, 1.35 0.57
CR3+ 1.92 1.10, 3.33 0.02 1.03 0.54, 1.98 0.93 1.43 0.94, 2.18 0.09
Advanced disease 3.73 2.74, 5.09 <0.001 1.43 1.03, 1.98 0.03 2.21 1.77, 2.77 <0.001
Cytogenetic
Good (ref) – – – – – – – – –
Interm 1.95 0.94, 4.03 0.07 0.85 0.53, 1.36 0.49 1.18 0.78, 1.78 0.43
Poor 2.88 1.33, 6.28 0.008 0.67 0.36, 1.25 0.21 1.09 0.68, 1.77 0.71
NA/failed 1.28 0.59, 2.80 0.53 1.02 0.61, 1.70 0.94 1.11 0.72, 1.72 0.64
Graft type : DCBT versus SCBT 0.98 0.75, 1.27 0.85 0.90 0.68, 1.18 0.44 0.93 0.77, 1.13 0.48
Conditioning type :
RIC versus MAC
1.44 1.07, 1.95 0.02 0.61 0.45, 0.83 0.002 0.81 0.65, 1.01 0.06
ATG used : yes versus no 1.04 0.77, 1.39 0.81 1.65 1.22, 2.25 0.001 1.37 1.11, 1.70 0.004
GVHD, graft-versus-host disease; aGVHD, acute GVHD; cGVHD, chronic GVHD; CR, complete remission; DCBT, double
umbilical cord blood transplantation; SCBT single umbilical cord blood transplantation; RIC, reduced-intensity
conditioning; MAC, myeloablative conditioning; ATG, anti-thymocyte globuline.
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cell source [28]). Notably, despite preventing acute
GVHD the use of ATG was associated with higher
nonrelapse mortality leading to worse OS. This is
in concordance with the results of previous studies
reported by the French group of bone marrow
transplantation [29, 30]. These results are also in
accordance with those reported by Admiraal et al.
who demonstrated that reducing the exposure of
ATG after UCBT (allowing early CD4+ T cell recov-
ery as observed in the PBSCT setting [31])
improved outcomes in paediatric UCBT [32].
Importantly, a recent study has observed that
administration MMF at the dose of 3 g day1
(instead of 2 g day1) decreased the incidence of
grade II–IV acute GVHD without affecting infec-
tion-related mortality of other transplantation
outcomes in the setting of double UCBT following
RIC conditioning [33].
Our study also confirms observations from our
group that the incidence of grade II–IV acute GVHD
is higher in double than in single-UCBT recipients
[34]. However, as also observed both in patients
transplanted myeloablative or RIC conditioning,
other transplantation outcomes were not signifi-
cantly improved in patients given two cord blood
units [34, 35].
Besides advanced disease status and poor risk
cytogenetics, this study also observed a higher risk
of disease relapse in patients transplanted follow-
ing RIC versus myeloablative conditioning, as
Fig. 2 Evolution of nonrelapse
mortality rates according to
GVHD status. Rates were
calculated within sequential
90-day intervals for patients
without GVHD (shown in blue),
for patients with grades II–IV
acute GVHD (shown in green)
or for patients with chronic
GVHD (shown in red). Small
symbols represent the actual
relapse rates for each 90-day
interval. The smoothed rates
were plotted as curves for each
condition.
Fig. 3 Evolution of mortality
rates according to GVHD
status. Rates were calculated
within sequential 90-day
intervals for patients without
GVHD (shown in blue), for
patients with grades II–IV acute
GVHD (shown in green) or for
patients with chronic GVHD
(shown in red). Small symbols
represent the actual relapse
rates for each 90-day interval.
The smoothed rates were
plotted as curves for each
condition.
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previously reported [25]. However, interestingly,
the conditioning intensity impacted the risk of
relapse only the first 18 months after UCBT but
had no impact thereafter. This suggests that graft-
versus-leukaemia effects are the main mechanisms
protecting for late relapses after UCBT. Other
approaches to decrease relapse incidence after
CBT might include posttransplant administration
of disease-targeted medications [36–39] or of
chimeric antigen receptor T cells [40].
Being a registry based study, there are some limi-
tations in our study including heterogeneity in term
of conditioning regimen and GVHD prophylaxis (we
tried to assess this limitation by performing multi-
variate analyses), and missing data on comorbidity
other than Karnofsky score, minimal residual dis-
ease and response of GVHD to therapy.
Conclusions
In summary, our study showed that despite poten-
tially increasing graft-versus-leukaemia effects,
occurrence of each grade II–IV acute or chronic GVHD
increases overall mortality after UCBT for AML. This
demonstrates that strategies aimed at better prevent-
ing GVHD are also requested in the UCBT setting.
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